Patent application number | Description | Published |
20090010924 | Apoptotic Anti-IgE Antibodies - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 01-08-2009 |
20100143352 | COMBINATION THERAPY FOR B CELL DISORDERS - The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist. | 06-10-2010 |
20100247430 | Methods and Compositions for Modulating T Cells - The invention provides methods and compositions useful for modulating T cells, and disorders associated with the dysregulation thereof. | 09-30-2010 |
20120144512 | TRANSGENIC ANIMALS EXPRESSING HUMAN IGE-M1' - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 06-07-2012 |
20120149881 | APOPTOTIC ANTI-IGE ANTIBODIES - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 06-14-2012 |
20120178127 | Nucleic acid encoding apoptotic anti-ige antibodies - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 07-12-2012 |
20140115729 | APOPTOTIC ANTI-IGE ANTIBODIES - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 04-24-2014 |
20140377257 | COMBINATION THERAPY FOR B CELL DISORDERS - The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist. | 12-25-2014 |